The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
mTORC1 and mTORC2 in cancer and the tumor microenvironment
Open accessAbstract
The mammalian target of rapamycin (mTOR) is a crucial signaling node that integrates environmental cues to regulate cell survival, proliferation and metabolism, and is often deregulated in human cancer. mTOR kinase acts in two functionally distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), whose activities and substrate specificities are regulated by complex co-factors. Deregulation of this centralized signaling pathway has been associated with a variety of human diseases including diabetes, neurodegeneration and cancer. Although mTORC1 signaling has been extensively studied in cancer, recent discoveries indicate a subset of human cancers harboring amplifications in mTORC2-specific genes as the only actionable genomic alterations, suggesting a distinct role for mTORC2 in cancer as well. This review will summarize recent advances in dissecting the relative contributions of mTORC1 versus mTORC2 in cancer, their role in tumor-associated blood vessels and tumor immunity, and provide an update on mTOR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E.-L., Mizushima, N., Ohsumi, Y., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20039 · Cited by 2,311
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Yue, Z., Jin, S., Yang, C., Levine, A. J., & Heintz, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436255100 · Cited by 2,116
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., Mukherjee, C., Shi, Y., Gélinas, C., Fan, Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.001 · Cited by 2,011
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., Belham, C., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14484 · Cited by 1,367
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
The role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Sestrin2 is a leucine sensor for the mTORC1 pathway
Wolfson, R. L., Chantranupong, L., Saxton, R. A., Shen, K., Scaria, S. M., Cantor, J. R., & Sabatini, D. M. (2016) · Science · doi:10.1126/science.aab2674 · Cited by 1,306
The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
Delgoffe, G. M., Kole, T. P., Zheng, Y., Zarek, P. E., Matthews, K. L., Xiao, B., Worley, P. F., Kozma, S. C., & Powell, J. D. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.014 · Cited by 1,284
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,229
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,080
mTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis
Paik, J.-H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z., Horner, J. W., Carrasco, D. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.029 · Cited by 1,032
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 854
Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
Wang, S., Tsun, Z.-Y., Wolfson, R. L., Shen, K., Wyant, G. A., Plovanich, M. E., Yuan, E. D., Jones, T. D., Chantranupong, L., Comb, W., et al. (2015) · Science · doi:10.1126/science.1257132 · Cited by 824
Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway
Han, J. M., Jeong, S. J., Park, M. C., Kim, G., Kwon, N. H., Kim, H. K., Ha, S. H., Ryu, S. H., & Kim, S. (2012) · Cell · doi:10.1016/j.cell.2012.02.044 · Cited by 824
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J. H., Asara, J. M., & Manning, B. D. (2016) · Science · doi:10.1126/science.aad0489 · Cited by 795
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
Differential regulation of mTORC1 by leucine and glutamine
Jewell, J. L., Kim, Y. C., Russell, R. C., Yu, F.-X., Park, H. W., Plouffe, S. W., Tagliabracci, V. S., & Guan, K.-L. (2015) · Science · doi:10.1126/science.1259472 · Cited by 757
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1
Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D. (2013) · Science · doi:10.1126/science.1228792 · Cited by 739
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Dowling, R. J. O., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 726
Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes
Blommaart, E. F. C., Luiken, J. J. F. P., Blommaart, P. J. E., van Woerkom, G. M., & Meijer, A. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.5.2320 · Cited by 686
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639
The TSC-mTOR pathway regulates macrophage polarization
Byles, V., Covarrubias, A. J., Ben-Sahra, I., Lamming, D. W., Sabatini, D. M., Manning, B. D., & Horng, T. (2013) · Nature Communications · doi:10.1038/ncomms3834 · Cited by 633
FOXO1 couples metabolic activity and growth state in the vascular endothelium
Wilhelm, K., Happel, K., Eelen, G., Schoors, S., Oellerich, M. F., Lim, R., Zimmermann, B., Aspalter, I. M., Franco, C. A., Boettger, T., et al. (2016) · Nature · doi:10.1038/nature16498 · Cited by 579
Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528
Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
Robitaille, A. M., Christen, S., Shimobayashi, M., Cornu, M., Fava, L. L., Moes, S., Prescianotto-Baschong, C., Sauer, U., Jenoe, P., & Hall, M. N. (2013) · Science · doi:10.1126/science.1228771 · Cited by 525
Mayer, C., Zhao, J., Yuan, X., & Grummt, I. (2004) · Genes & Development · doi:10.1101/gad.285504 · Cited by 505
PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding
Wang, L., Harris, T. E., Roth, R. A., & Lawrence, J. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702376200 · Cited by 494
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
Self-citationOvercoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Guo, F., Wang, Y., Liu, J., Mok, S. C., Xue, F., & Zhang, W. (2016) · Oncogene · doi:10.1038/onc.2015.139 · Cited by 468
Lee, K., Gudapati, P., Dragovic, S., Spencer, C., Joyce, S., Killeen, N., Magnuson, M. A., & Boothby, M. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.002 · Cited by 464
The utilization of extracellular proteins as nutrients is suppressed by mTORC1
Palm, W., Park, Y., Wright, K., Pavlova, N. N., Tuveson, D. A., & Thompson, C. B. (2015) · Cell · doi:10.1016/j.cell.2015.06.017 · Cited by 457 · cited 3×
“mTORC1 inhibition may also cause increased cell proliferation within vascularly compromised tumor regions due to elevated micropinocytosis (60) of extracellular proteins or increased cell survival through enhanced autophagy (65).”
BackgroundPathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
The ever-expanding role of HIF in tumour and stromal biology
LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 430
Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2
Humphrey, S. J., Yang, G., Yang, P., Fazakerley, D. J., Stöckli, J., Yang, J. Y., & James, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.010 · Cited by 411
mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation
Pollizzi, K. N., Patel, C. H., Sun, I.-H., Oh, M.-H., Waickman, A. T., Wen, J., Delgoffe, G. M., & Powell, J. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77746 · Cited by 411
Masui, K., Tanaka, K., Akhavan, D., Babic, I., Gini, B., Matsutani, T., Iwanami, A., Liu, F., Villa, G. R., Gu, Y., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.013 · Cited by 407
PtdIns(3,4,5) P 3-Dependent Activation of the mTORC2 Kinase Complex
Liu, P., Gan, W., Chin, Y. R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L. C., Toker, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0460 · Cited by 382
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-Feldstein, J., Cordon-Cardo, C., Celeste Simon, M., Rafii, S., & Pandolfi, P. P. (2006) · Nature · doi:10.1038/nature05029 · Cited by 378
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Architecture of human mTOR complex 1
Aylett, C. H. S., Sauer, E., Imseng, S., Boehringer, D., Hall, M. N., Ban, N., & Maier, T. (2016) · Science · doi:10.1126/science.aaa3870 · Cited by 344
Leucyl-tRNA Synthetase Controls TORC1 via the EGO Complex
Bonfils, G., Jaquenoud, M., Bontron, S., Ostrowicz, C., Ungermann, C., & De Virgilio, C. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.02.009 · Cited by 340
Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
Carrière, A., Cargnello, M., Julien, L.-A., Gao, H., Bonneil, É., Thibault, P., & Roux, P. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.07.078 · Cited by 336
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis
Thedieck, K., Polak, P., Kim, M. L., Molle, K. D., Cohen, A., Jenö, P., Arrieumerlou, C., & Hall, M. N. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001217 · Cited by 296
A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
Yang, G., Murashige, D. S., Humphrey, S. J., & James, D. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.016 · Cited by 295
Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP
Ricoult, S. J. H., Yecies, J. L., Ben-Sahra, I., & Manning, B. D. (2016) · Oncogene · doi:10.1038/onc.2015.179 · Cited by 281
Bakker, W. J., Harris, I. S., & Mak, T. W. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.10.035 · Cited by 277
Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D., Gini, B., Dang, J., Zhu, S., Yang, H., De Jesus, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0124 · Cited by 275
Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D., & Sillaber, C. (2002) · Blood · doi:10.1182/blood-2002-01-0109 · Cited by 273
Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 259
Browne, G. J., & Proud, C. G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2986-2997.2004 · Cited by 256
Masri, J., Bernath, A., Martin, J., Jo, O. D., Vartanian, R., Funk, A., & Gera, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2223 · Cited by 253
Lane, H. A., Wood, J. M., McSheehy, P. M. J., Allegrini, P. R., Boulay, A., Brueggen, J., Littlewood-Evans, A., Maira, S.-M., Martiny-Baron, G., Schnell, C. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2057 · Cited by 249
Multiple amino acid sensing inputs to mTORC1
Shimobayashi, M., & Hall, M. N. (2016) · Cell Research · doi:10.1038/cr.2015.146 · Cited by 223
mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
Pusapati, R. V., Daemen, A., Wilson, C., Sandoval, W., Gao, M., Haley, B., Baudy, A. R., Hatzivassiliou, G., Evangelista, M., & Settleman, J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.018 · Cited by 222
mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1
Kantidakis, T., Ramsbottom, B. A., Birch, J. L., Dowding, S. N., & White, R. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005188107 · Cited by 218
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
Chatterjee, S., Heukamp, L. C., Siobal, M., Schöttle, J., Wieczorek, C., Peifer, M., Frasca, D., Koker, M., König, K., Meder, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65385 · Cited by 195
The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex
Heikamp, E. B., Patel, C. H., Collins, S., Waickman, A., Oh, M.-H., Sun, I.-H., Illei, P., Sharma, A., Naray-Fejes-Toth, A., Fejes-Toth, G., et al. (2014) · Nature Immunology · doi:10.1038/ni.2867 · Cited by 193
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
Weiler, M., Blaes, J., Pusch, S., Sahm, F., Czabanka, M., Luger, S., Bunse, L., Solecki, G., Eichwald, V., Jugold, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314469111 · Cited by 188
Stracka, D., Jozefczuk, S., Rudroff, F., Sauer, U., & Hall, M. N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.574335 · Cited by 188
Enhanced radiation damage of tumor vasculature by mTOR inhibitors
Shinohara, E. T., Cao, C., Niermann, K., Mu, Y., Zeng, F., Hallahan, D. E., & Lu, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208715 · Cited by 183
Shor, B., Wu, J., Shakey, Q., Toral-Barza, L., Shi, C., Follettie, M., & Yu, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.071639 · Cited by 182
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
Sommer, E. M., Dry, H., Cross, D. A. E., Guichard, S. M., Davies, B. R., & Alessi, D. R. (2013) · Biochemical Journal · doi:10.1042/bj20130342 · Cited by 168
Viñals, F., Chambard, J. C., & Pouysségur, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.26776 · Cited by 165
SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
Gasser, J. A., Inuzuka, H., Lau, A. W., Wei, W., Beroukhim, R., & Toker, A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.023 · Cited by 149
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 149
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Basu, B., Dean, E. J., Puglisi, M., Greystoke, A., Ong, M., Burke, W., Cavallin, M., Bigley, G., Womack, C., Harrington, E. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2422 · Cited by 143
Dolly, S. O., Wagner, A. J., Bendell, J. C., Kindler, H. L., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M. P., Apt, D., Yeh, R.-F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2225 · Cited by 143
Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2
Gaubitz, C., Oliveira, T. M., Prouteau, M., Leitner, A., Karuppasamy, M., Konstantinidou, G., Rispal, D., Eltschinger, S., Robinson, G. C., Thore, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.031 · Cited by 142
Powles, T. B., Lackner, M. R., Oudard, S. M., Escudier, B. J., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8808 · Cited by 137
Mahadevan, D., Chiorean, E. G., Harris, W. B., Hoff, D. D. V., Stejskal-Barnett, A., Qi, W., Anthony, S. P., Younger, A., Rensvold, D., Cordova-Marks, F. M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.027 · Cited by 136
Naing, A., Aghajanian, C. A., Raymond, É., Olmos, D., Schwartz, G., Oelmann, E. M., Grinsted, L. M., Burke, W., Taylor, R., Kaye, S. B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.368 · Cited by 135
Zhang, L., Tschumi, B. O., Lopez-Mejia, I. C., Oberle, S. G., Meyer, M., Samson, G., Rüegg, M. A., Hall, M. N., Fajas, L., Zehn, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.095 · Cited by 134
Fokas, E., Im, J. H., Hill, S. A., Yameen, S., Stratford, M. R. L., Beech, J. S., Hackl, W., Maira, S.-M., Bernhard, E. J., McKenna, W. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2263 · Cited by 131
Shapiro, G. I., Bell‐McGuinn, K. M., Molina, J. R., Bendell, J. C., Spicer, J. F., Kwak, E. L., Pandya, S. S., Millham, R., Borzillo, G. V., Pierce, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1306 · Cited by 127
del Campo, J. M., Birrer, M. J., Davis, C. B., Fujiwara, K., Gollerkeri, A. M., Gore, M. E., Houk, B. E., Lau, S. K., Poveda, A. M., González-Martín, A., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.019 · Cited by 122
Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia
Lee, K., Nam, K. T., Cho, S. H., Gudapati, P., Hwang, Y., Park, D., Potter, R. M., Chen, J., Volanakis, E. J., & Boothby, M. R. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111470 · Cited by 119
Self-citationMünster, P. N., Aggarwal, R. R., Hong, D. S., Schellens, J. H. M., van der Noll, R., Specht, J. M., Witteveen, P. O., Werner, T. L., Dees, E. C., Bergsland, E. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1665 · Cited by 114
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Zhang, J., Xu, K. L., Liu, P., Geng, Y., Wang, B., Gan, W., Guo, J., Wu, F., Chin, Y. R., Berrios, C. J., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.023 · Cited by 108
Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0971 · Cited by 104
Powles, T. B., Wheater, M. J., Din, O. S., Geldart, T., Boleti, E., Stockdale, A. D., Sundar, S., Robinson, A., Ahmed, I., Wimalasingham, A. G., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.08.035 · Cited by 103
Bendell, J. C., Kurkjian, C. D., Infante, J. R., Bauer, T. M., Burris, H. A., Greco, F. A., Shih, K. C., Thompson, D. S., Lane, C. M., Finney, L. H., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0218-6 · Cited by 101
Zhuang, G., Yu, K., Jiang, Z., Chung, A. S., Yao, J. J., Ha, C., Toy, K. J., Soriano, R. H., Haley, B., Blackwood, E. R., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003572 · Cited by 96
Papadopoulos, K. P., Tabernero, J. M., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J. M., Shi, W., Égile, C., Ruiz-Soto, R., Laird, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2403 · Cited by 96
Wen, P. Y., Omuro, A. M. P., Ahluwalia, M. S., Fathallah‐Shaykh, H. M., Mohile, N. A., Lager, J. J., Laird, A., Tang, J., Jiang, J., Égile, C., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov083 · Cited by 94
Plasticity beyond Cancer Cells and the “Immunosuppressive Switch”
Granot, Z., & Fridlender, Z. G. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1502 · Cited by 93
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2 -Amplified Breast Cancers
Joly, M. M., Hicks, D. J., Jones, B. A., Sanchez, V. M., Estrada, M. V., Young, C. D., Williams, M. M., Rexer, B. N., Sarbassov, D. D., Muller, W. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3393 · Cited by 92
Self-citationFazio, N., Buzzoni, R., Baudin, É., Antonuzzo, L., Hubner, R. A., Lahner, H., de Herder, W. W., Raderer, M., Teulé, À., Capdevila, J., et al. (2016) · PubMed · Cited by 85
Bendell, J. C., Kelley, R. K., Shih, K. C., Grabowsky, J. A., Bergsland, E. K., Jones, S. F., Martin, T., Infante, J. R., Mischel, P. S., Matsutani, T., et al. (2015) · Cancer · doi:10.1002/cncr.29422 · Cited by 81
Roy, D., Sin, S., Lucas, A., Venkataramanan, R., Wang, L., Eason, A. B., Chavakula, V., Hilton, I. B., Tamburro, K. M., Damania, B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1851 · Cited by 80
Britten, C. D., Adjei, A. A., Millham, R., Houk, B. E., Borzillo, G. V., Pierce, K. J., Wainberg, Z. A., & LoRusso, P. M. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0062-5 · Cited by 79
Requirement for Rictor in homeostasis and function of mature B lymphoid cells
Lee, K., Heffington, L., Jellusova, J., Nam, K. T., Raybuck, A. L., Cho, S. H., Thomas, J. W., Rickert, R. C., & Boothby, M. R. (2013) · Blood · doi:10.1182/blood-2013-01-477505 · Cited by 77
Wang, S., Amato, K. R., Song, W., Youngblood, V., Lee, K., Boothby, M. R., Brantley‐Sieders, D. M., & Chen, J. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00306-14 · Cited by 70
Self-citationSun, S., Chen, S., Liu, F., Wu, H., McHugh, J. B., Bergin, I. L., Gupta, A., Adams, D. M., & Guan, J. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.004 · Cited by 69
Mateo, J., Olmos, D., Dumez, H., Poondru, S., Samberg, N. L., Barr, S. M., Tornout, J. M. V., Jie, F., Sandhu, S. K., Tan, D. S. W., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.59 · Cited by 68
Seront, E., Rottey, S., Filleul, B., Glorieux, P., Goeminne, J., Verschaeve, V., Vandenbulcke, J., Sautois, B. R., Boegner, P., Gillain, A., et al. (2016) · British Journal of Urology · doi:10.1111/bju.13415 · Cited by 61
Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis
Farhan, M., Carmine-Simmen, K., Lewis, J. D., Moore, R. B., & Murray, A. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135245 · Cited by 51
Janne, P. A., Cohen, R. B., Laird, A., Macé, S., Engelman, J. A., Ruiz-Soto, R., Rockich, K. T., Xu, J., Shapiro, G. I., Martínez, P., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000088 · Cited by 49
mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis
Morrison, M. M., Young, C. D., Wang, S., Sobolik, T., Sanchez, V. M., Hicks, D. J., Cook, R. S., & Brantley‐Sieders, D. M. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005291 · Cited by 45
Self-citationPapadopoulos, K. P., Égile, C., Ruiz‐Soto, R., Jiang, J., Shi, W., Bentzien, F., Rasco, D., Abrisqueta, P., Vose, J. M., & Tabernero, J. M. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.974040 · Cited by 32
Resolving Molecular Events in the Regulation of Meiosis in Male and Female Germ Cells
Kumar, S., Cunningham, T. J., & Duester, G. (2013) · Science Signaling · doi:10.1126/scisignal.2004530 · Cited by 28
Cited by
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
mTOR as a central hub of nutrient signalling and cell growth
Kim, J., & Guan, K.-L. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0205-1 · Cited by 1,072
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Metadata
- Authors
- Kim, L. C., Cook, R. S., & Chen, J.
- Venue
- Oncogene
- Published
- 2016-10-17
- Volume
- 36
- Issue
- 16
- Pages
- 2191-2201
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2535462468
- Cited by
- 444
- References
- 147
- FWCI
- 17.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.